Search

OBJECTIVE To evaluate intraoperative and postoperative complications and outcomes following subconjunctival enucleations with and without third eyelid removal in domestic rabbits. ANIMALS 18 client-owned rabbits with ocular disease confined to the globe that underwent 20 subconjunctival enucleation procedures at a veterinary teaching hospital. METHODS Records were retrospectively reviewed for all enucleations performed at a veterinary teaching hospital from 2014 to 2022. A standard subconjunctival enucleation procedure was performed in all cases, with third eyelid removal in 2 surgeries and without third eyelid removal in the remaining 18 surgeries. Outcomes were assessed on the basis of observations in medical records and owner follow-up. RESULTS 20 total enucleations were included. Reported reasons for enucleation included suspected or confirmed ocular Encephalitozoon cuniculi infection in 9 rabbits, refractory glaucoma in 4 rabbits, and various intraoculardiseases in 5 rabbits. The only intraoperative complication reported was hemorrhage during the third eyelid removal in 1 surgery. Postoperative complications included serous to mucoid discharge from the surgical site in 8 of 20 surgeries and swelling at the surgery site in 2 of the 8 cases that had discharge. Postoperative swelling spontaneously resolved within 3 months of surgery; postoperative discharge spontaneously resolved within 10 months of surgery. CLINICAL RELEVANCE Subconjunctival enucleation with or without third eyelid removal in rabbits may be a viable enucleation technique to reduce the risk for intraoperative hemorrhage, but it can result in postoperative complications, including transient discharge and swelling at the surgical site. [ABSTRACT FROM AUTHOR]

Objective: To establish pilot data on the plasma concentrations of SC amikacin at 2 doses in red-eared sliders and evaluate concurrent plasma biochemistry parameters., Animals: 8 adult red-eared sliders (Trachemys scripta elegans)., Methods: Amikacin was administered SC at target doses of 5 and 10 mg/kg with a 3-week washout period. Blood samples were collected at 0, 24, 48, 72, and 96 hours postadministration. Plasma amikacin concentrations were quantified using liquid chromatography tandem mass spectrometry. Plasma biochemistry analyses were performed before amikacin administration, 1 week post 5-mg/kg administration, and 1 week post 10-mg/kg administration., Results: Mean maximum amikacin plasma concentrations were recorded 24 hours after 5-mg/kg and 10-mg/kg dosing and were 17.5 ± 2.32 µg/mL and 23.6 ± 2.92 µg/mL, respectively. Mean plasma concentrations after 5-mg/kg dosing steadily decreased to 9.1 ± 0.92 µg/mL by 96 hours postadministration. Amikacin remained detectable in all plasma samples 3 weeks post 5-mg/kg dosing with a mean plasma concentration of 1.04 ± 0.22 µg/mL. Mean plasma concentrations after 10-mg/kg dosing did not decrease over the 96-hour study period. There were no clinically relevant changes in biochemistry parameters., Clinical Relevance: Amikacin persists at detectable plasma levels for at least 3 weeks after SC administration of a 5-mg/kg dose in red-eared sliders, which has not previously been reported in any species. No biochemistry changes consistent with renal toxicity occurred after either dose. Use caution with repeated amikacin dosing in this species until further studies can better characterize cumulative amikacin pharmacokinetics and toxic threshold.